Abciximab-induced thrombocytopenia: Correct management

Creative Commons License

Kelkitli E., Odabaşi Giden A., Denız Kürekçi D., Turgut M.

Journal of Experimental and Clinical Medicine (Turkey), cilt.39, sa.2, ss.581-583, 2022 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.52142/omujecm.39.2.58
  • Dergi Adı: Journal of Experimental and Clinical Medicine (Turkey)
  • Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.581-583
  • Anahtar Kelimeler: Abciximab, glycoprotein IIb/IIIa receptor inhibitors, side effect, thrombocytopenia
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. This case reported the development of thrombocytopenia and treatment management after using abciximab.